RWD92 Evaluation of Second and Third Generation Tyrosine Kinase Inhibitor As First-Line Therapy for Non–Small-Cell Lung Cancer Patients: A Multi-Institutional Study in Taiwan
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.2809
https://www.valueinhealthjournal.com/article/S1098-3015(23)05939-9/fulltext
Title :
RWD92 Evaluation of Second and Third Generation Tyrosine Kinase Inhibitor As First-Line Therapy for Non–Small-Cell Lung Cancer Patients: A Multi-Institutional Study in Taiwan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05939-9&doi=10.1016/j.jval.2023.09.2809
First page :
Section Title :
Open access? :
No
Section Order :
12143